0001610717-24-000511.txt : 20241018 0001610717-24-000511.hdr.sgml : 20241018 20241018182519 ACCESSION NUMBER: 0001610717-24-000511 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20241017 FILED AS OF DATE: 20241018 DATE AS OF CHANGE: 20241018 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Fust Matthew K CENTRAL INDEX KEY: 0001397266 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-41802 FILM NUMBER: 241381648 MAIL ADDRESS: STREET 1: C/O ULTRAGENYX PHARMACEUTICAL INC. STREET 2: 60 LEVERONI COURT CITY: NOVATO STATE: CA ZIP: 94949 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Neumora Therapeutics, Inc. CENTRAL INDEX KEY: 0001885522 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 844367680 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 490 ARSENAL WAY, SUITE 200 CITY: WATERTOWN STATE: MA ZIP: 02472 BUSINESS PHONE: (857) 760-0900 MAIL ADDRESS: STREET 1: 490 ARSENAL WAY, SUITE 200 CITY: WATERTOWN STATE: MA ZIP: 02472 FORMER COMPANY: FORMER CONFORMED NAME: RBNC Therapeutics, Inc. DATE OF NAME CHANGE: 20210929 4 1 form4.xml X0508 4 2024-10-17 0001885522 Neumora Therapeutics, Inc. NMRA 0001397266 Fust Matthew K C/O NEUMORA THERAPEUTICS, INC. 490 ARSENAL WAY, SUITE 200 WATERTOWN MA 02472 true true Common Stock 2024-10-17 4 M 0 3783 8.32 A 23883 D Common Stock 2024-10-17 4 M 0 1800 8.79 A 25683 D Common Stock 2024-10-17 4 M 0 2156 2.52 A 27839 D Common Stock 2024-10-17 4 S 0 7739 17.0103 D 20100 D Common Stock 2024-10-18 4 M 0 6205 8.79 A 26305 D Common Stock 2024-10-18 4 M 0 7844 2.52 A 34149 D Common Stock 2024-10-18 4 S 0 14049 17.0346 D 20100 D Stock Option (Right to Buy) 8.32 2024-10-17 4 M 0 3783 0 D 2030-09-07 Common Stock 3783 0 D Stock Option (Right to Buy) 8.79 2024-10-17 4 M 0 1800 0 D 2030-09-07 Common Stock 1800 6205 D Stock Option (Right to Buy) 2.52 2024-10-17 4 M 0 2156 0 D 2031-04-22 Common Stock 2156 93430 D Stock Option (Right to Buy) 8.79 2024-10-18 4 M 0 6205 0 D 2030-09-07 Common Stock 6205 0 D Stock Option (Right to Buy) 2.52 2024-10-18 4 M 0 7844 0 D 2031-04-22 Common Stock 7844 85586 D The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on May 10, 2024. This transaction was executed in multiple trades in prices ranging from $17.00 to $17.045, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. This transaction was executed in multiple trades in prices ranging from $17.00 to $17.15, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. The shares subject to the option are fully vested and exercisable. /s/ Joshua Pinto, as Attorney-in-Fact for Matthew K. Fust 2024-10-18